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ABSTRACT
Autism Spectrum Disorder (ASD) is a neurodevelopmental condition
affecting approximately 1% of the population. It occurs roughly four times more in
males than females, and includes individuals with classic autism, as well as
those with “incomplete” forms. Behavioral characteristics include, but are not
limited to: restricted, stereotyped, and repetitive actions, as well as impairments
in communication and social interaction. At the Greenwood Genetics Center,
Greenwood, SC, ASD patients and control donors provided peripheral blood as a
source of lymphocytes, and a skin-scrape sample as a source of fibroblasts for
genetic analysis. A severely autistic patient, coded as B26, his two parents
(mother Y17, father VT8), and two donor controls (JOR, RT9) were compared.
Patient and donor lymphocytes were transformed into immortal lymphoblast lines
using EBV-transformation procedures. In addition to routine genetic analysis,
both fibroblasts and lymphoblasts were evaluated by GGC researchers as a
possible platform to generate neuronal cells through iPS steps. Attempts were
successful with fibroblasts, but not lymphoblasts. In this thesis, these five
lymphoblast lines were evaluated for possible association with ASD and both
parents, along with two donor controls. These cells were also examined for their
potential in other areas of research, including the autocrine production of
inflammatory and anti-inflammatory cytokines, reactivation of RAG-1 as a
consequence of EBV-transformation, pharmacological and toxicological
applications mediated through the AHR, and their metabolic responses to
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tryptophan exposure. All five cell lines produce significant quantities of the
autocrine B-cell growth factor IL-6, and, to a lesser degree, IL-10, before and
after further activation with phorbol ester in combination with calcium ionophore.
Patient B26 and his two parents produced the most cytokine in response to
activation, while the control donors had a higher baseline production. All five
cells lines expressed RAG-1 protein, indicating reactivation of B-cell receptor
diversity process that may lead to a different BCR specificity. In pharmacology
and toxicology, many xenobiotics and endogenous metabolites of tryptophan act
through the AHR leading to induction of phase I, II, and III enzymes. The
classical marker of AHR activity is the induction of CYP1B1. In response to
FICZ, a potent tryptophan intermediate, patient B26 had the highest level of
CYP1B1 induction, followed by Y17, the mother. Because tryptophan is
metabolized by IDO2 in activated normal lymphocytes, the induction of IDO2 was
quantified after activation with phorbol ester and calcium ionophore. Expression
of IDO2 was highest in patent B26, followed by Y17, the mother. Recent
research at GGC suggests that tryptophan is metabolized differently in ASD
patients when compared to donor controls.

A commercially available PCR array

of genes associated with tryptophan metabolism was then employed and
revealed that key genes involved in tryptophan metabolism are not altered in the
severely autistic patient B26, either of B26’s two parents (mother Y17, father
VT8), nor the two donor controls (JOR, RT9). The array also showed that several
genes involved in mitochondrial function were highly responsive to tryptophan
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treatment in B26, and similarly in the mother, Y17. Genes not only involved in
energy metabolism, but also inflammation and different pathways stemming from
tryptophan metabolism (serotonin and melatonin pathways) were increased.
This study shows that lymphoblasts generated from ASD patients and donor
controls may have use outside of the field of autism research, and may lead to
the development of novel biomarkers for screening individuals for ASD.
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LITERATURE REVIEW
ASD is a behavioral syndrome that is usually revealed during early
childhood and is hypothesized to reflect underlying neurodevelopmental
abnormalities [1]. Core symptoms of ASD include abnormal or unreciprocated
interpersonal interactions, muddled language and communication, and repetitive
and stereotypic behavior [2]. Several biomarkers have been associated with
ASD, but there are currently no laboratory tests to be used as concrete
diagnostic tools [3]. The etiology of ASD has brought upon much divisiveness
among scientists and the general public in recent years. There has been a
dramatic climb in the number of children diagnosed with one of the ASDs, with
the most severe form being autistic disorder [4]. In the United States alone, the
diagnosis of ASD has increased almost ten-fold over the last decade [5]. This
increase is seen as alarming because in the 1980’s, there were roughly 4-5
children per 10,000 diagnosed. In the 1990’s, there were about 30-60 children
diagnosed per 10,000 people [6]. Some scientists believe that a main cause of
this upsurge is the result of heightened awareness of ASD now compared to the
1980s. Some believe that it is the change in diagnostic criteria, suggesting that
the number of people with ASD has stayed stable over time [7]. There are few
studies that have been designed to definitively address whether the true
prevalence of ASD has stayed stable or increased during time, but many agree
that it would be premature to state that there is no increase in prevalence [8].
Most diagnoses are based upon behavioral symptoms, which have been well
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described. Much less research is focused on the causes of these symptoms. This
begs the question of why - why are the core symptoms of ASD social disinterest,
problems in communication, and overly focused behavior? Where do these
behaviors internally stem from? The goal of this literature review is to highlight
the relevance of prior studies in the development of this thesis as it pertains to
ASD from a genetic standpoint, as well as cytokine involvement and AhR
activation in ASD patients.
A previous study analyzed the metabolic profile of lymphoblast cell lines
from 137 patients with neurodevelopmental disorders with and without ASD and
78 control individuals [9]. This and another study looked at individuals with ASD
versus control patients, and saw that the ASD patients exhibited on average
reduced generation of NADH when tryptophan was the sole energy source [10].
The results correlated with the behavioral traits associated with either syndromal
or non-syndromal autism, but it did not seem to matter what the genetic
background of the individual was [11]. A low level of NADH generation in the
presence of tryptophan was observed in cell lines from ASD patients, but not in
cell lines from non-ASD patients with either intellectual disability, schizophrenia
or similar conditions to ASD except for the behavioral traits [12].
Analysis of a previous small gene expression study found abnormal levels
for some genes involved in tryptophan metabolic pathways in 10 patients [13]. It
can be hypothesized that the observed reduction of tryptophan metabolism in
ASD cell lines may come from any abnormal function along tryptophan metabolic
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pathways in the cells [14]. Some of the most frequently reported findings in ASD
brains are increased brain size and increased white matter [15]. It is possible that
impairment of the kynurenic pathway may have consequences on the pruning
process in the brain and lead to an excess of white matter [16]. Microglial cells
are considered to be responsible for keeping the proper balance between
quinolinic and kynurenic acid, since they are able to secrete both compounds
[17]. The expression of those molecules is strongly influenced by the activity of
the immune system, which has been implicated as impaired in ASD individuals in
a number of studies.
Tryptophan is also the main precursor for both melatonin and serotonin.
Melatonin plays a critical role in the regulation of the circadian rhythm, and
disturbances in this rhythm have been associated with several symptoms in ASD,
like seizures or sleep disorders [18]. Serotonin is an important neurotransmitter
involved in many functions, from the regulation of mood to the control of appetite
and social interactions, and its production has been reported as deficient in the
brains of ASD individuals [19]. Since tryptophan levels have been shown to
influence central nervous system serotonin levels and behavior, it can be
concluded from these studies that an altered tryptophan transport exists in
patients with ASD [20].
The cell lines studied included a severely autistic child, B26, as well as the
two parents of the patient with ASD and two donor controls (JOR and RT9). B26
has inherited microdeletions on chromosomes 10p12.31 and 15q15.3 from each
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parent respectively. These microdeletions on the corresponding chromosomes
have been associated with developmental delay, low muscle tone, and
communication difficulties, and ASD. It would be advantageous to know how, or
if, a combination of chromosomal deletions could be linked to the severity of
ASD, and to look at the evolution of genome sequencing. In the twentieth
century, knowledge about human genetic variation was limited mainly to the
heterochromatin polymorphisms, and single nucleotide polymorphisms (SNPs)
identified by traditional PCR-based DNA sequencing. In the past ten years, the
swift development and extended use of microarray technologies, such as the
commercial array used in this study as well as next-generation sequencing, has
enabled a whole-genome analysis with essentially unlimited resolve [21]. The
discovery of submicroscopic copy-number variations (CNVs) present in our
genomes has changed the perspective on DNA structural variation and disease.
CNVs have been shown to be responsible for susceptibility to traits (genomic
disorders), genetic diversity, and human evolution. In addition, many common
complex traits including autism can result from CNVs. Since CNVs can involve
part of a gene or even several genes, some CNVs are likely to have a role in the
alteration of human physiological functions, causing disease [22]. They therefore
are likely to be subject to evolutionary pressures such as selection and genetic
drift.
Altered immune response in ASD individuals has been reported for almost
40 years [23], and there is evidence that suggests increased inflammation in the
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brain and CNS based upon specimens obtained from individuals with ASD [24].
Several studies have shown immune differences in children with ASD, such as
abnormal cytokine profiles [25]. A subset of studies have demonstrated
increased levels of inflammatory cytokines in ASD, such as IL-6 and increased
levels of IL-10 [26]. However, varied experimental designs, diagnostic criteria,
varying ages in comparison of ASD patients with donor controls (children with
ASD vs. adult controls) have caused misinterpretation of the results [27]. Small
sample sizes have posed a challenge in the ability to detect differences in
cytokine patterns between ASD patients and donor controls, and this is
showcased in the current study.
Lastly, countless studies have indicated that cells from patients with ASD,
on average, are less capable of utilizing tryptophan as an energy source than
controls. Although not published yet, a study by Dr. William Baldwin has
showcased that B26 fibroblasts contain more mitochondria but are insufficient at
mitochondrial repair and response to oxidative stress. This is shown through an
array of important genes in tryptophan metabolism. Moreover, findings in these
studies were consistent in patients across the autism spectrum and was not
influenced by age or sex. Decreased tryptophan metabolism in patients with
ASDs may alter metabolic pathways involved in the regulation of the early stages
of brain development, mitochondrial homeostasis and immune system activity in
the brain [28].
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INTRODUCTION
Autism Spectrum Disorder (ASD) is a neurodevelopmental condition
affecting approximately 1% of the population. It occurs roughly four times more
likely in males than females, and includes individuals with classic autism, as well
as those with “incomplete” forms of autism [29]. People with ASD fall on a
spectrum between low functioning and high functioning, and the severity ranges
from patient to patient. Behavioral characteristics include, but are not limited to:
restricted, stereotyped, and repetitive actions, as well as impairments in
communication and social interaction. A strong genetic predisposition for ASDs
has been inferred from a higher concordance in identical twins (between 30%60%), as compared to fraternal twins (roughly 6%) [30]. The higher concordance
rate found in identical twins suggests that multiple genes are related to the cause
of autism. The combination of affected genes and the environment both play a
role in the development of ASD. There is no particular laboratory test to diagnose
ASD, although several biomarkers have been associated with it [31]. The cause
of ASD is not known and likely involves interactions between environmental, and
most importantly, genetic factors.
Links to environmental factors in the development of ASD focus on
contaminants involved in air pollution, and especially persistent organic pollutants
(POPs). This includes PCBs, dioxins, and furans, as well as some polycyclic
aromatic hydrocarbons, such as benzo-a-pyrene, which is also found in
secondary smoke from tobacco use [32]. Many of these environmental
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pollutants are ligands for the aryl hydrocarbon receptor (AHR), a ligand activated
transcription factor that leads to the induction of phase I xenobiotic metabolizing
enzymes, such as CYP1B1 and CYP1A1 [33]. While no studies have linked the
expression of, or genetic variants of AHR with causes of autism, and no studies
have shown differences between AHR expression and variants in control vs.
patients, there is a correlation between expression and severity score [34]. One
of the most potent of AHR ligands is 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD),
and exposure is associated with a plethora of syndromes, including wasting,
hepatocellular carcinoma, chloracne, reproductive toxicity, thymic atrophy, and
immune dysfunction; the underlying mechanism may be the loss of NAD+ [35].
In some ASD patients, altered tryptophan metabolism also leads to the loss of
NAD+ [36], which may hint to altered AHR signaling in some ASD patients.
Moreover, the induction of CYP1B1 and CYP1A1 by some environmental
pollutants may lead to extremely toxic, mutagenic, and teratogenic intermediate
metabolites. To date, little is known about the role of AHR, phase I enzyme
activities, and ASD.
The expression of CYP1B1 can be induced by a number of endogenous
ligands, including tryptophan and its metabolites through the AHR [37] [38]. In
addition, CYP1B1 is involved in the metabolism of many important physiological
compounds including arachidonic acid, estrogen, melatonin and retinoids [39]. In
previous research, genes that are known to be involved in tryptophan
metabolism, such as CYP1B1, were examined in a small subset of patients with
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ASD. It was found that these patients expressed CYP1B1 at higher levels than
those without autism. A previous study done by Smerdova et al. demonstrated
that there was an upregulation of CYP1B1 expression in ASD individuals
because of an increase in inflammatory cytokines and aryl hydrocarbon ligands
[40].
Recent papers have described links between genes that encode for
immune-related proteins such as IL-6 and IL- 10 and ASD, suggesting that
abnormalities in the immune system may impair brain development [41].
Interleukin-6 was originally labeled B-cell growth factor because it is critical to the
growth and proliferation of myeloma cells, but is also known as a classical
marker of macrophage-associated inflammation, and known to be required for
normal neurological development and physiology [42, 43]. Intereukin-6 is of
interest because studies have suggested that brain IL-6 is an important mediator
of autism-like behaviors [44] [45].
Current evidence dictates that IL-6 may have a crucial role within the
CNS. In the CNS, IL-6 can trigger cellular responses such as inflammation, cell
growth, neurogenesis, and cell survival among other processes [46]. IL-6 is
ordinarily expressed at reasonably low levels in the brain, but in the presence of
injury or inflammation, IL-6 is elevated in spinal fluid as well as brain
homogenate. In a study done by Wei, H. et al., it was shown that chronic
overexpression of IL-6 in mice causes anatomical and physiological changes in
the brain, leading to disorders such as ASD [47].

8

Interleukin-10 (IL-10) is a well-known anti-inflammatory cytokine that plays
an important role in preventing inflammatory pathologies [48]. Gerber et al. found
that an increase in cathepsin D, a protease abundantly expressed in the brain,
can trigger secretion of cytokines, including IL-10 due to a corresponding
increase in pro-inflammatory cytokines, such as IL-6 [49]. This could suggest that
IL-10 acts in a negative feedback loop, or a homeostasis, for when levels of IL-6
increase.
Some research suggests that patients along the ASD scale have an
altered ability to utilize tryptophan [50]. Tryptophan is an essential amino acid
and needs to be supplemented via diet. It is also an AhR agonist and precursor
of many important compounds such as kynurenic acid, serotonin, and quinolinic
acid – all of which are involved in neurodevelopment and the formation of
synapses [51].
The majority of tryptophan is metabolized along the kynurenine-quinolinic
pathway of tryptophan degradation, and follows two other major pathways of
metabolism in the GI tract: transformation by microbiota in the gut of tryptophan
into ligands of the aryl hydrocarbon receptor (AhR), and the serotonin production
pathway [52]. This is demonstrated in illustration 1. Decreased tryptophan
production seen in ASD individuals may alter development of the brain, immune
activity, and mitochondrial function. Studies have shown that the abnormal
utilization of tryptophan as an energy source further supports possible
mitochondrial dysfunction [53].
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Metabolism of tryptophan via the kynurenine-quinolinic pathway leads to
the synthesis of NAD+, while the serotonin branch of the tryptophan metabolic
pathway generates NADH. Serotonin functions as a key neurotransmitter and
serves as a communication system between the central nervous system and the
GI tract [54]. The microbial impact on the metabolism of tryptophan and the
serotonin pathway may be important in the regulation of the brain-gut axis. It has
been previously concluded that individuals with ASD may have a decreased
diversity of gut microbiota, dictating serotonin-related health problems [55]. This
could be related to the ability of the microbiota in the gut to control metabolism of
tryptophan along the kynurenine pathway, therefore reducing the amount of
tryptophan needed for serotonin synthesis.
Observing decreased levels of NADH generation in the presence of
tryptophan may indicate reduced utilization of tryptophan resulting from
downregulation of metabolic reactions at any point along the two pathways. The
kynurenines produced during the kynurenine-quinolinic pathway via indoleamine
2,3-dioxygenase 2 are potent ligands for the AhR, and are involved mainly in
inflammatory response, immune response, and excitatory neurotransmission
[56]. Indoleaminedioxygenases 1 & II (IDO1, IDO2) are induced by various pro‐
inflammatory cytokines (such as IL-6). Therefore, in immune‐activated
environments, IDO may break down a large proportion of tryptophan leading to a
shortage for the serotonin–melatonin pathway. It has been observed that in some
ASD patients, there is a dysfunction in a number of genes involved in the
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kynurenine-quinolinic pathway and the serotonin pathway compared to donor
controls, namely the production of IL-6 [57].
As previously mentioned, a portion of tryptophan is metabolized in the GI
tract and transformed by microbiota in the gut into ligands of the AHR. Since the
AHR contains a promiscuous ligand-binding pocket, it can bind multiple classes
of exogenous compounds. The photo-oxidation product of tryptophan, 6formylindolo(3,2-b) carbazole, otherwise known as FICZ, is one of the more
potent endogenous ligands for the AHR and may be the primary metabolite of
indole-3-carbinol (I3C) during digestion, which has been found to modulate the
expression and activity of biotransformation enzymes involved in metabolism and
excretion of many biologically active compounds [58]. In addition, FICZ induces
AHR translocation to the nucleus and transcription of the AHR target gene
CYP1B1, as demonstrated in illustration 2. Polymorphisms of some AHR-induced
genes in ASD individuals may cause an increase in CYP1B1 production,
therefore a possible increase in severity of ASD [59]. The expression of
indoleamine dioxygenases (IDO) is involved in catabolism of tryptophan and is
believed to be a major source of tryptophan dysfunction in ASD patients. In other
studies, it is hypothesized that there is an increased level of IDO, resulting in an
increased catabolism of tryptophan [60]. This means that tryptophan is possibly
metabolized too quickly and being delegated to the AHR rather than other
tryptophan pathways such as the serotonin pathway.
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While progress in ASD research has been made, where studies have
attempted to evaluate whether cytokine levels are associated with onset of
stereotypical behaviors in ASD, there are still many shortcomings in finding a
definitive diagnostic tool in a clinical setting for a concrete diagnosis. As of now,
there are no laboratory tests that can accurately diagnose ASD. Therefore,
diagnosis is based upon observed stereotypical behaviors associated with ASD.
Many children are not diagnosed until the age of 2 or 3, meaning that the window
to intervene early is essentially closed before a diagnosis is even made [61].
Researchers at the Greenwood Genetics Center, Greenwood SC USA,
are intensely focused on autism research. As part of a larger, long term study,
ASD patients and control donors have provided peripheral blood as a source of
lymphocytes, and a skin-scrape sample as a source of fibroblasts, both for
genetic analysis. Patient and donor lymphocytes were transformed into immortal
lymphoblast lines using EBV-transformation procedures. In addition to routine
genetic analysis, both fibroblasts and lymphoblasts were evaluated by GGC
researchers as a possible platform to generate neuronal cells through iPS steps.
Attempts were successful with fibroblasts, but not lymphoblasts. However, these
lymphoblasts lines from ASD patients and donor controls may hold promise in
aspects of autism research outside of iPS-derived neuronal cells, or even outside
of autism research.
EBV-transformed B-cells to lymphoblasts are known to secrete IL-6 in an
autocrine fashion to stimulate continuous proliferation [62], and levels can be
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increased by further activation with phorbol esters (e.g., phorbol ester myristate –
PMA). It is now known that activiation can be improved by the addition of
calcium ionophore (e.g., A23187, ionomycin), and this combination is routinely
used in current research protocols. The addition of PMA activates
Calcium/phospholipid-dependent PKC, and calcium ionophore A23187 increases
intracytosolic free calcium concentration [63]. Together, PMA and A23187
bypass the early activation pathways and promote B‐cell growth through the
direct induction of membrane IL‐6 receptor expression and IL‐6 synthesis and
secretion. Also, EBV-lymphoblast-derived IL-6 has been used as a source to
stimulate the growth of human myeloma cells. These cells also secrete IL-10 as
a negative control against over stimulation by IL-6 [64]. It has been observed
that in some, but not all EBV-transformed lymphoblast lines, that RAG-1/RAG-2
genes are reactivated in terminally activated lines from continuous culture, and
may be an indication of full activation [65].
Little is known about the AHR activities in EBV-derived lymphoblasts,
including baseline AHR expression levels and induction of CYP1B1 by AHR
ligands, but one study showed that AHR activation leads to EBV-reactivation in
latent infected B-cells, which may lead to Sjogren’s Syndrome [66]. The
questions of how do EBV-transformed lymphoblasts respond to AHR ligands is
an open question, and fertile ground for future research. Moreover, this is even
more so for EBV-transformed lymphoblasts derived from ASD patients.
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To my knowledge there is no consensus on how tryptophan is
metabolized by EBV-transformed B-cells in general, but metabolism of this
critical amino acid during other chronic viral diseases has been examined [67].
Tryptophan depletion by IDO and AHR both depletes tryptophan needed by the
pathogen, and contributes to the state of local immunosuppression induced by
metabolites, because prolonged activation of the AHR leads to
immunosuppression [67]. Whether or not tryptophan metabolism in chronically
activated EBV-transformed lymphoblasts from a severe ASD patient is different
than donor controls is one of the key questions asked in my thesis.
The purpose of the research for this thesis is to characterize lymphoblasts
cell lines derived from ASD patients and control donors to determine if there are
intrinsic differences in levels of secretion of autocrine growth factors IL-6 and IL10, in states if activation, expression of AHR and CYP1B1 involved in the
metabolism of endogenous indoles, and differences in gene expression
pathways involved in tryptophan metabolism. A severely autistic patient, coded
as B26, his two parents (mother Y17, father VT8), and two donor controls (JOR,
RT9) were compared. It is my hope that this information will be a spring board
for the next set of approaches using these cell lines, and for the development of
possible screening biomarkers for differences between ASD patients and those
not diagnosed with ASD.
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METHODS
Study subjects
First, peripheral blood lymphocytes from ASD patients and donor controls
were provided to Greenwood Genetics Center and transformed to immortal B-cell
lymphoid cell lines using EBV transformation. Cells from each subject were
coded by internal referencing numbers, and later given an abbreviated name.
This study focuses on one patient with severe ASD having deletions 10p12.31
and 15q15.3, inherited from the mother and father, respectively. The patient with
ASD was given the code B26. The patient’s parents were given code Y17
(mother) and VT8 (father), and the other two donor controls were coded RT9 and
JOR.
The following general procedure for transforming B-cells to lymphoblast is
as follows. First, mL of blood was drawn from each donor and diluted with 20 mL
of PBS at room temperature. The diluted blood was subsequently put into
separation media and centrifuged at 225 x g at room temperature for 30 minutes.
Concentrated white blood cells that collected at the top were removed, and the
sample was diluted with PBS up to 50 mL. Samples were spun down once more
at 600 x g at room temperature for 10 minutes. After centrifugation, supernatant
was poured off, and the cells were washed by re-suspending the pellet in 50 mL
PBS, and spinning down at the same settings. This was repeated twice more.
Once the cells were washed, they were re-suspended in 1 mL of fresh media.
Ten microliters of cells were used for counting.
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Infection with EBV
Methods for transforming B-cells followed previously published methods
[68, 69], and carried out by researchers at the Greenwood Genetics Center
(GGC), Greenwood, SC USA. Exponentially growing B95-8 cells (ATCC # CRL
1612; 13) at 3 x 105 cells/ml in a 75cm2 tissue culture flask were maintained
using sterile technique. Cells are grown in complete RPMI 1640 containing 10%
heat-inactivated fetal bovine serum (FBS), Penicillin/Streptomycin at 100U/ml
and 100 μg/ml, respectively, and Amphotericin B at 0.5 μg/ml at 37°C in the
presence of 5% CO2. To ensure virus production, the cells were stimulated with
20ng/mL tetradecanoyl phorbol acetate (TPA; a.k.a. PMA) for 1 hour in a
standard CO₂ incubator. The cells were then washed three times with the media
to remove the TPA. Cells were re-suspended in the same amount of fresh media
previously mentioned and placed in a flask inside of the incubator for 96 hours.
After the incubation time, cells were centrifuged at 600 x g in order to separate
the supernatant containing EBV. The supernatant containing virus was then
filtered out through a 0.45 µn filter, partitioned, and stored at -70°C. Peripheral
blood cells from patients and donors were mixed with virus-containing
supernatants as previously described, and stimulated with phyohemmaglutin-A
(PHA). FK506, a T cell immunosuppressant, was added to the cell suspension
from above, and placed into the incubator at 37°C for 1 hour. After incubation, an
aliquot of EBV previously prepared was added to the flask at a 1/10 dilution. The
flask was swirled and sat upright in the incubator for 3 days. Cells were
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subsequently cloned and verified to be B-cell blast using flow cytometry with Bcell-specific antibody markers.
Both the ASD and donor control human lymphocyte cell lines were stored
at GGC, and also maintained at Clemson University. Cells are grown in
Dulbecco’s modified Eagle’s medium (DMEM; Corning) supplemented with 20%
heat inactivated fetal calf serum (Thermo Fisher), 25mM HEPES, 4.5 g/L
glucose, 110 µg/mL sodium pyruvate, 10 mM L-glutamate, 100 U/mL penicillin,
100 µg/mL streptomycin, 20 mg/mL Gentamicin, 10 mg/mL Nystatin, 1% MEM
Non-Essential Amino Acids (100X), and 7.5% sodium bicarbonate, each from
Sigma (Sigma Aldrich, St. Louis MO, USA). Cells were grown and maintained at
37°C in a standard incubator in 75 cm² culture flasks.

Expression of IL-6 and IL-10 in untreated and stimulated cell lines
Cell lines were maintained prior to manipulation as described above. Two
separate conditions were investigated. In the first set or experiments, cells were
seeded at 2 x 10⁶ cells/mL in T-25 cm² Corning culture flasks, in triplicate, and
supernatants collected at the start of culture, and again at 6 and 12 hr to
determine baseline production of IL-6 and IL-10. This was to determine the
relative rate of production by each line, but also to determine the relative
magnitude of production. In the second set of experiments, the same culture
conditions were maintained, except that each cell line was treated with either
0.01% DMSO containing media, or the same with the addition of 1 uM PMA + 0.5
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M A23187, which bypasses the B-cell receptor signaling pathways to activate
PKC-delta, NFK-beta, and AP-1 to stimulate production of cytokines. IL-6 and IL10 were both quantified by Human IL-6 ELISA MAX Deluxe Set (Biolegend) and
Human IL-10 ELISA MAX Deluxe Set (Biolegend) respectively, following
directions provided by the supplier.

Expression of RAG-1 and AHR protein
Two million lymphoblasts were seeded in T-25 flasks in 3 ml of media and
incubated for 24 hr. Cells were removed from each flask and pelleted by
centrifugation and covered with 500 μl RIPA lysis buffer (50 mM Tris HCl, pH 8,
150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, and 0.1% SDS)
containing protease inhibitor cocktail (Pierce). The cell pellet was disrupted by
gentle vortexing, and incubated on ice for 30 min. Thirty micrograms of whole cell
lysate protein from each sample were separated by SDS-PAGE on 4-20% gels
(Biorad) and transferred overnight onto 0.2 PDVF membranes (Thermofisher) at
4 °C. For RAG-1 detection, whole mouse thymus lysate (Novus Biologicals) was
examined as a positive control. For AHR detection, cell lysates from the human
glioblastoma cell line T98G (ATCC) were used due to the high amount of AHR
expressed in these cells [70]. The membranes were washed three times with
0.01 M phosphate buffered saline (PBS) containing 0.1% tween-20 (PBS-tw20),
covered with blocking buffer (10% FCS in PBS) for 1 h and again washed three
times with PBS-tw20. Membranes were then probed for 2 h with either rabbit
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anti-human RAG-1 antibody (RNF4; Abcam) at 2 ug/ml, mouse monoclonal antihumann AHR (mAb A-3; Santa Cruz) at 2 ug/ml, or mouse monoclonal anti-β
actin (Sigma Aldrich) at 2 ug/ml. Antibodies were diluted in PBS-tw20 containing
1% FCS. The blots were washed three times for 10 min with PBS-tw20, and
probed for 2 h with either goat anti-rabbit IgG, or goat anti-mouse IgG secondary
antibody conjugated with alkaline phosphatase (ThermoFisher) diluted 1:1000 in
PBS-tw20 containing 1% FCS. After extensive washings with PBS-tw20, alkaline
phosphatase activity was determined using the substrate NBT-BCIP to visualize
the relative amount of specific protein.

Expression of CYP1B1 and IDO2 mRNA
To quantify CYP1B1 and IDO2 mRNA expression, each cell line was
cultured in T-24 cm3 flasks as described above, and treated with 10 nM FICZ (for
CYP1B1 expression), or 1 uM PMA + 0.5 M A23187, (for IDO2 expression) for 12
hr. PMA + A23187 by passes the B-cell receptor signaling pathways to activate
PKC-delta, NFK-beta, and AP-1 to stimulate IDO2 expression. The treatments
were done in triplicate for each cell line. Following the treatment regimen, each
sample was centrifuged, and a pellet was formed from each of the three
replicated experiments. RNAzol (Molecular Research) was added (1 mL) to cell
pellets, and the mixture was homogenized by pipetting gently several times.
Samples were stored at -4°C until ready to use. Total RNA was isolated using
protocol supplied by the manufacturer. First strand cDNA synthesis was carried
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out using the RT² Easy First Strand Kit (SABioscience Corporation) as outlined
by the manufacturer. Gene expression was evaluated by quantitative PCR with a
BioRad iC5 detection system, RT² SYBR green master mix, and primer sets
designed using Integrated DNA technology software. The primer sets were
validated prior to use, and the quantity of mRNAs was expressed as fold
changes using GAPDH as a housekeeping gene. Primer sets and relative
information are as below.

.
Table 1. Primer sets for quantifying CYP1B1 and IDO2 induction
For data analysis, the ΔΔCt method was used, and data was compared between
treatments using ANOVA.

Commercial qPCR array for genes involved in tryptophan metabolism
Lymphoblastoid cells were seeded at 2 x 10⁶ cells/mL in 75 cm² Corning
culture flasks. Cells were then treated for 24 h with 2 mM tryptophan as
recommended by others [71]. This experimental regimen was repeated three
times and the lymphocytes were pooled (n = 3) per treatment regimen, then
collected after centrifugation to have one pooled pellet from each of the three
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replicated experiments. One milliliter of TRI-reagent® (Molecular Research) was
added to cell pellets and the mixture was homogenized by gently pipetting
several times. The homogenate was incubated at room temperature for 5 min
and 0.2 mL chloroform was added. Total RNA was then isolated via
manufacturer instruction. After collecting RNA from each tube, DNA
contamination was removed using an elimination mixture supplied by the
manufacturer, and first strand cDNA synthesis was carried out using the RT2
Easy First Strand Kit (SABioscience Corporation) as described by the
manufacturer. A predesigned Amino Acid Metabolism ProfilerTM array of 96
genes was purchased from SuperArray Bioscience Corporation for use with RT2
Real-Timer SYBR Green/ fluorescein qPCR master mixes purchased from the
same supplier. Specific methods followed those suggested by the manufacturer.
QPCR was performed on a BioRad iQ5 real-time PCR detection system. For
data analysis, the ΔΔCt method was used; for each gene, fold-changes were
calculated as difference in gene expression between untreated controls and
treated cell cultures. Data were gathered and interpreted using software provided
by SABioscience. The goal was to determine which genes may be of interest to
follow up with, confirmed using regular qPCR.
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RESULTS
IL-6 and IL-10 expression in untreated cell lines, and cell stimulated with PMA +
A23187
Interleukin-6 secretion in lymphoblast lines was compared to background
levels in complete media, and shown vary from line to line, but was higher in both
control donors than in B26 and the two parents (Figure 1A). This was the case
for both 6 hr and 12 hr incubation. Under these conditions donor JOR produced
the most IL-6, followed by donor RT9. Interleukin-10 secretion by lymphoblasts
under the same culturing conditions was higher than IL-6, with the two donor
controls secreting the most (Figure 1B). At 6r, IL-10 secretion by VT8 (the father)
was also high, and nearly matched the two donor lines. By 12 hr, IL-10 levels in
the father’s line (VT8) were lower, as were the others.

Figure 1. Interleuking-6 and IL-10 secretion by lymphoblast cell lines at 6 hr and
12 hr culture. Cells were grown in complete media only, and without further
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treatment. Cytokine levels were quantified by ELISA, and the data represent the
mean +/- S.E. of levels above that measured in complete media without cells.
In response to PMA + A23187, IL-6 and IL-10 secretion was quantified as
an indicator of the ability of lymphoblast to increase production beyond
background. Cells generated from patient B26 responded with a robust increase
in secretion of IL-6 secretion at 12 (Figure 2A), with the expected increase over
time. Likewise, Y17 cells (the mother) responded to stimulation with a large
increase in production over time (Figure 2B). This was also observed in VT8
cells (the father) in response to stimulation over time (Figure 2C). Cells derived
from the two donor controls did not respond as well as the other three, with RT9
producing a modest amount at 6 hr, and much less at 12 hr (Figure 2D), while
donor JOR produced very little IL-6 at 6r, and nothing significant at 12 hr (Figure
2E). These observations are nearly reversed of what was produced by
unstimulated cells (Figure 2).
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Figure 2. Interleuking-6 secretion by lymphoblast cell lines at 6 hr and 12 hr
culture after stimulation with PMA + A23187. Cytokine levels were quantified by
ELISA, and the data represent levels above non-stimulated cells. Data represent
the mean +/- S.E. of fold increase above baseline secretion in three separate
experiments. *** = p < .001, * = p < .05.
Interleukin-10 secretion by B26 cells was increased significantly at 6r and
12 hr, but the levels at 12 hr were less than at 6 hr (Figure 3A). Similar
responses were observed in Y17 cells (Figure 3B), though the magnitude was
less than that of B26. Responses to stimulation in VT8 cells were higher at 6 hr,
but not 12 hr (Figure 3C). For RT9 cells, IL-10 secretion was significantly
increased by stimulation for 6 hr, but not 12 hr (Figure 3D). As was observed
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with IL-6 production in response to stimulation, JOR cells produced very low
levels of IL10 upon stimulation (Figure 3E).

Figure 3. Interleuking-10 secretion by lymphoblast cell lines at 6 hr and 12 hr
culture after stimulation with PMA + A23187. Cytokine levels were quantified by
ELISA, and the data represent levels above non-stimulated cells. Data represent
the mean +/- S.E. of fold increase above baseline secretion in three separate
experiments. *** = p < .001, ** = p < .01.

Expression of RAG-1 and AHR in lymphoblast cell lines
Cellular expression of recombination activation gene-1, RAG-1, evident in
all 5 cell lines with slight reduction in Y17 cells (Figure 4). These levels were as
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high as can be seen in the mouse thymocyte lysate (Thy), and all bands were at
the expected MW of approximately 135 kDa.

Figure 4. Expression of RAG-1 protein in whole cell lysates from lymphoblast
cell lines. Thirty ug of lysate protein were subjected to SDS-PAGE and
immunoblotting using a RAG-1-specific antibody. Equal amounts of protein were
subjected SDS-PAGE and immunoblotting using a β-actin specific antibody.
Whole mouse thymus tissue lysates (Thy) were used as a positive control for
RAG-1
Cellular expression of the AHR was evident in all 5 cell lines, with a slight
reduction in the Y17, and perhaps VT8 (Figure 5, Figure 6). These proteins were
of the expected molecular weight of approximately 100 kDa, and were expressed
at about the same level as lysates from the glioblastoma cell line (GLI).
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Figure 5. Expression of AHR protein in whole cell lysates from lymphoblast cell
lines. Thirty ug of lysate protein were subjected to SDS-PAGE and
immunoblotting using a AHR-specific antibody. Equal amounts of protein were
subjected SDS-PAGE and immunoblotting using a β-actin specific antibody.
Human glioblastoma T98G cell lysates (GLI) were used as a positive control for
RAG-1
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Figure 6. Band density of AHR expression in lymphoblasts. Bands density was
determined using Image J software (NIH).

CYP1B1 and IDO2 expression as markers for the trypto-AHR pathway
In response to the endogenous AHR ligand FICZ, CYP1B1 induction was
highest in B26 cells, and was significantly higher than the other four cells lines
(Figure 6A). When examining for differences in CYP1B1 mRNA levels between
all pair-wise comparisons, there we no differences between the V17, VT8, JOR,
and RT9. Expression levels in VT8, JOR, and RT9 were roughly two-fold, with
Y17 cells expressing close to 4 fold levels, and B26 cells expressing nearly twice
that level.
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In response to PMA + A2317 as a means to activate the cells to induce
expression of IDO2, B26 cells responded more than the other four cell lines
(Figure 6B). When examining for differences in IDO2 mRNA levels between all
pair-wise comparisons, there we no differences between the V17, VT8, JOR, and
RT9. Expression levels in Y17, VT8, JOR, and RT9 were roughly 3 – 4 fold, with
B26 cell expressing nearly twice that level.

Figure 7. CYP1B1 mRNA induction in lymphoblast cells lines following 12 hr
treatment with FICZ (A). IDO2 mRNA induction in lymphoblast cells lines
following 12 hr treatment with PMA + A23187 (B). Data represent the mean +/S.E. of fold increase over GAPDH mRNA expression in three separate
experiments. *** represent p < .001.

Effects of tryptophan on expression of genes involved in tryptophan metabolism
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A commercially available qPCR array platform for evaluating tryptophan
metabolism was used as a screening approach to determine if treatment with
tryptophan modulates changes in mRNA expression of genes involved in
tryptophan metabolism in the lymphoblasts. The data provides an indication of
relative magnitude of expression compared to DMSO controls and allows
observation of relative changes in gene expression associated with inflammation,
apoptosis, cell cycle control, and oxidative stress. Under these conditions, some
of the lymphoblasts exhibit an increased expression of several mRNAs
associated with activation, signaling, pro-inflammatory, and catabolism of
tryptophan available on this array (Figure 1). For each mRNA evaluated on the
array, treatment either decreased expression (more than 2-fold suppression),
had no effect, or only slightly increased (2-fold or higher). Of note, B26 was the
very high expresser for some genes involved in energy conversion/metabolism,
melatonin synthesis, and genes involved biosynthesis of arginine (ACADM,
AANAT, ACAT1, ACMSD, ALDH18A1, ARG2, ASL, and BHMT). For B26, all of
these genes were significantly expressed (>10-fold). It can be noted that both
Y17 and VT8, the parents of B26, had some of the same significant increases in
some genes similar to B26, namely ACADM, ACAT1, ALDH18A1. Several
mRNAs were intermediate in expression (>2-fold, <10-fold).
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Gene name
Aminoadipate aminotransferase
Aralkylamine N-acetyltransferase
Acyl-CoA dehydrogenase medium chain
Acetyl-CoA acetyltransferase 1
Aminocarboxymuconate semialdehyde decarboxylase
Aldehyde dehydrogenase 9, family member A1
Aldehyde dehydrogenase 18, family member A1
Amine oxidase, Cu containing 1
Aldehyde oxidase 1
Arginase 2
Argininosuccinate lyase
Betaine-homocysteine S-methyltransferase
Catalase
CYP1B1
DOPA decarboxylase
Enoyl-CoA hydratase and 3-hydroxyacyl CoA dehydrogenase
Glutaryl-CoA dehydrogenase
3-hydroxyanthranilate 3,4-dioxygenase
Indoleamine 2,3-dioxygenase 1
Indolethylamine N-methyltransferase
Kynurenine 3-monooxygenase
Kynureninase
Monoamine oxidase B
Nitrilase family member 2
Oxoglutarate dehydrogenase like
Tryptophan 2,3-dioxygenase 2
Tryptophan hydroxylase 2
Tryptophanyl-tRNA synthetase

Genbank #
NM_016228
NM_001088
NM_000016
NM_000019
NM_138326
NM_000696
NM_002860
NM_001091
NM_001159
NM_001172
NM_000048
NM_001713
NM_001752
NM_000104
NM_000790
NM_001966
NM_000159
NM_012205
NM_002164
NM_006774
NM_003679
NM_003937
NM_000898
NM_020202
NM_018245
NM_005651
NM_173353
NM_004184

Symbol
AADAT
AANAT
ACADM
ACAT1
ACMSD
ALDH9A1
ALDH18A1
AOC1
AOX1
ARG2
ASL
BHMT
CAT
CYP1B1
DDC
EHHADH
GCDH
HAAO
IDO1
INMT
KMO
KYNU
MAOB
NIT2
OGDHL
TDO2
TPH2
WARS

B26
-1.70
17.13
13746.90
140.28
12.93
3.52
11.83
-1.70
-1.70
12.10
17.25
24.51
1.61
7.58
1.06
2.78
2.19
1.10
-10.35
2.39
1.02
1.56
-1.70
1.53
-1.16
-2.18
-1.70
1.03

VT8
-1.70
10.87
2947.08
19.32
2.51
1.45
11.24
-1.70
-3.85
3.73
3.70
-1.60
-1.02
5.56
-2.06
-4.13
1.08
1.07
-1.70
-1.70
1.28
1.51
-1.70
1.45
1.68
-1.70
-1.70
1.53

Y17

JOR
1.39
1.03
-1.17
-1.19
-5.36
-1.07
-2.28
1.39
1.39
-1.07
-1.22
-17.29
-1.48
-1.06
1.41
-1.05
-1.05
-1.49
1.39
-7.24
-3.92
-3.12
1.39
-1.82
2.24
1.39
-2.31
-1.11

F34
1.75
-3.87
2.44
2.51
-2.38
-1.26
3.11
45.14
1.28
1.53
1.28
1.64
-1.29
-3.34
1.09
-1.27
1.51
1.52
-5.62
-1.06
-1.28
1.36
-1.70
-1.70
-1.70
-1.70
1.05
-1.15

PO1
1.91
2.95
2.37
1.64
6.49
1.59
3.75
1.91
-2.09
1.88
1.88
1.75
2.12
-2.05
-1.42
2.48
1.49
1.28
1.91
1.91
1.54
1.03
1.91
-1.48
-1.19
4.28
1.91
1.10

4.75
1.15
136.42
3.56
-1.68
2.34
24.90
1.92
1.92
-1.26
-1.28
1.92
-2.31
1.83
3.88
3.03
-1.50
-1.42
1.92
1.92
-2.12
-2.47
1.92
-1.60
2.31
1.92
1.92
1.43

T48
7.53
8.30
848.69
23.93
12.29
21.18
23.21
-1.41
-1.41
6.51
5.40
4.10
4.26
29.25
-1.41
7.43
1.44
2.10
5.32
-6.46
2.75
3.85
-1.41
29.33
1.02
1.80
-1.41
2.36

Table 2 shows an array outlining fold change in genes involved in tryptophan
metabolism for all cell lines using a commercial qPCR Amino Acid Metabolism
Array
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GN12
-1.55
2.31
1.66
1.59
1.48
1.32
1.14
-1.55
-1.55
1.43
1.10
10.78
1.15
2.58
1.89
1.57
-1.02
1.39
-1.55
-4.06
-1.12
1.03
-1.55
2.39
-1.22
-1.55
-1.07
1.31

DISCUSSION
In this study I found that lymphoblasts from ASD patient B26 stand out from the
other 4 cell lines and may provide a wealth of information in the fields of
inflammation, AHR biology, toxicology, mitochondrial functions, and possibly
others, including ASD. This cell line secretes low basal levels of IL-6 compared
to other lines but responded very well to stimulation with PMA + A23187 by
secreting more IL-6 than the other lines. This observation suggests that PKC,
NFkB, AP-1 and other signaling components are intact. Though not examined in
this study, studies examining fibroblast mitochondrial numbers are much higher
in B26 than the other lines, and if this holds true for B26 lymphoblasts, then that
may explain the rapid growth of this line compared to the others. The control
donor cells secreted high background levels of IL-6 in comparison to B26 and his
two parents, and may be useful in generating IL-6 supernatants to support
hybridomas during the production of monoclonal antibodies, since mouse cells
respond to human IL-6 [72]. The high levels of CYP1B1 induction by the
endogenous AHR ligand FICZ suggests that AHR signaling in B26 cells is not
altered by the EBV-transformation process, and this cell line may prove useful in
future studies examining AHR biology. This study can draw no conclusions that
would suggest the other 4 cell lines have impaired AHR signaling, but a few of
the lines expressed less AHR protein than did B26. All 5 lines expressed levels
of RAG-1 comparable to fresh mouse thymocytes, which are a rich source of
RAG-1, suggesting that RAG-1 has been reactivated during the EBV-
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transformation process. During normal B-cell development, RAG-1 (and RAG-2)
are expressed at two key check points to generate a functional heavy chain,
followed by the generation of a functional light chain, then the expression is
turned off in a mature B-cell. It may be that the transformation process drives the
B-cell back towards a pre-B-cell stage in which RAG-1 is re-expressed. RAG-1
may also be re-expressed during receptor editing when B-cell has the opportunity
to generate a new light chain if the original light chain recognizes “self”. These
cell lines may provide a model for RAG-1 genetics. To my knowledge, there is no
relationship between RAG-1 expression and ASD.
In this study it was found that key genes involved in tryptophan
metabolism are not altered in patient B26, either of its parents, nor the two donor
controls. The mother of B26, VT8, was likewise responsive to tryptophan in
terms of CYP1B1 induction. The array data shows that several genes involved in
mitochondrial function were very responsive to tryptophan treatment in B26, and
similarly in the mother, Y 17. Genes not only involved in energy metabolism, but
also inflammation and different pathways stemming from tryptophan metabolism
(serotonin and melatonin pathways) were affected. Although not yet published,
studies in Dr. William Baldwin’s lab at Clemson University show that fibroblasts
from B26 have very high numbers of mitochondria compared to other patients
and donors, but B26 fibroblasts did not demonstrate ample repair mechanisms
during hydrogen peroxide oxidative stress associated with mitochondria, and
mitochondrial repair. Similar observations were made in Y17, the mother of B26.
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CYP1B1 and IDO2 are two genes expressed in tryptophan metabolism
pathways, though the commercial array did not have IDO2 as one of the primer
sets. CYP1B1 is expressed when the AHR is activated, as seen with treatment
with FICZ in the qPCR experiments – FICZ us a potent endogenous ligand for
the AHR. IDO2 is expressed during the catabolism of tryptophan in a variety of
tissues, and especially activated lymphocytes, leading to the formation of
intermediate metabolites, several of which are known ligands for the AHR. An
increase in these two genes in ASD individuals could point to a dysfunctional
metabolism of tryptophan and its metabolites. Only one severely autistic patient
is represented in my study, but CYP1B1 and IDO2 may be expressed at higher
levels in people with ASD because tryptophan is broken down rapidly, therefore
favoring the AHR and being infrequently utilized in other pathways, such as the
serotonin pathway. Kynurenine plays an important role in preventing autoimmune
responses by generating regulatory T-cells through the activation of AHR. In
ASD, it seems that tryptophan is directed away from the kynurenine pathway and
results in a decreased production of kynurenine [73]. Low kynurenine is
associated with a lower than normal regulatory T- cell production (Treg) and a
higher risk of developing autoimmunity. This is demonstrated by the increased
catabolism of tryptophan in ASD patients compared to donor controls. However,
there is no current evidence that ASD is an autoimmune disease, but there may
be a link, and my results with B26 may lead to further studies on this subject.
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There is no rapid laboratory test to diagnose ASD, although several
biomarkers have been associated with it – namely altered tryptophan
metabolism. My study may provide a few biomarkers, such as B-cell activation by
PMA + A23187, peripheral lymphocyte CYP1B1 induction by FICZ, and IDO2
induction by PMA + A23187. It may be too cumbersome to use a commercial
tryptophan metabolism array such as the one I used, but perhaps select genes
associated with mitochondrial function would be appropriate.
The cause of ASD is not known and likely involves interactions between
genetic factors and environmental factors. Previous articles have shown that
there is a link between an over-expression of IL-6 and increased severity in ASD
symptoms. IL-6 is ordinarily expressed at reasonably low levels in the brain, but
in the presence of injury or inflammation, IL-6 is elevated in spinal fluid as well as
brain homogenates [74]. In a study done by Wei, H. et al., it was shown that
chronic overexpression of IL-6 in mice causes anatomical and physiological
changes in the brain, leading to disorders such as ASD. IL-10 is a well-known
anti-inflammatory cytokine, and increased levels could point to a negative
feedback loop type process. As levels of IL-6 increase, levels of IL-10 increase to
try and lower IL-6. In this study, levels of IL-6 and IL-10 in non-stimulated
lymphoblasts were observed. It seems as though IL-6 levels are lowest in B26
and the parents of B26, and perhaps because IL-10 helps to blunt inflammation,
therefore decreasing IL-6 levels.
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Typically, many children with ASD are not diagnosed until the age of 2 or
3, meaning that the window to intervene early is essentially closed before a
diagnosis is even made [61]. Even then, diagnosis depends on parent
questioning, and seems subjective. As mentioned before, B26, the severely
autistic child, has abnormalities on chromosome 10 and 15, both inherited from
the parents Y17 and VT8. It is important to note that although Y17 (mother) has
not been placed on the the autism spectrum, she had very similar responses to
tryptophan as B26 (the child), as seen in the IL-6 and IL-10 figures. All of these
data may point to more than a genetic association between specific
chromosomal deletions and ASD. It was previously mentioned that there are
thousands of submicroscopic structural variants covering up to roughly 18% of
the human reference DNA sequence, which means that no one micro deletion or
duplication points to ASD. It does mean, though, that there could be a possible
way to diagnose ASD with genetic testing when the child is still very young,
especially in families who have already had a child or children with ASD. My
assays and methods may be used in combination with analysis of genes involved
in mitochondrial function to shed light on the possibility of an earlier diagnosis.
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FUTURE DIRECTION
Moving forward from this study, a larger pool of study subjects
(lymphoblast lines) would be beneficial, as there were only five subjects treated
in this study. This would be especially helpful in performing another commercial
amino acid array, or even RNAseq, as more cell lines would aide in possible links
between these genes and severity of ASD. Although it was beneficial to have
samples from the parents of B26, because it assisted in seeing a possible role of
genetics in the development of ASD, it would have been more helpful to have
more samples from patients with ASD of varying severity. As mentioned
previously in this study, there was only one patient with severe ASD. ASD is a
spectrum, as the name suggests, and being able to connect expression of genes
and proteins of interest to the known severity of patients would have facilitated
data to possibly be able to not only diagnose ASD with a simple blood test, but
also the severity of the condition from an earlier age than when ASD is currently
diagnosed.
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Illustration 1 outlines the main intracellular pathways involving tryptophan,
as well as the genes involved in tryptophan metabolism
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Illustration 2 summaries the pathway of AhR-mediated transcription after
binding. The AHR and ligand are displaced from the cytoplasm to the
nucleus after binding, leading to transcription of both CYP1B1 and
IDO2 in this study
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APPENDIX A
Some genes highly expressed by B26, and the mother, Y17
Acetyl-CoA Acetyltransferase (ACAT1): This gene encodes an enzyme
located in the mitochondria that catalyzes the reversible formation of acetoacetylCoA from two molecules of acetyl-CoA. The ACAT enzyme is activated
by potassium ions binding near the CoA binding site and the catalytic site. This
binding causes a structural change in the active site loop. Additionally, this
enzyme is able to use 2-methyl-branched acetoacetyl-CoA as a substrate,
making it a unique thiolase. ACAT1 is regulated at both transcriptional and
translational levels. ACAT1’s expression is promoted transcriptionally by leptin,
angiotensin II, and insulin in human monocytes. Insulin-mediated regulation also
involves ERK, p38MAPK, and JNK signaling pathways.

Aralkylamine N-acetyltransferase (AANAT): The protein encoded by this gene
belongs to the acetyltransferase superfamily. It is the penultimate enzyme
in melatonin synthesis and controls the night/day rhythm in melatonin production
in the vertebrate pineal gland. Melatonin is essential for the function of
the circadian clock that influences activity and sleep. This enzyme is regulated
by cAMP-dependent phosphorylation that promotes its interaction with 14-3-3
proteins and thus protects the enzyme against proteasomal degradation.
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Aminocarboxymuconate Semialdehyde Decarboxylase (ACMSD): The
neuronal excitotoxin quinolinate is an intermediate in the de novo synthesis
pathway of NAD from tryptophan, and has been implicated in the pathogenesis of
several neurodegenerative disorders. Quinolinate is derived from alpha-aminobeta-carboxy-muconate-epsilon-semialdehyde (ACMS). ACMSD (ACMS
decarboxylase; EC 4.1.1.45) can divert ACMS to a benign catabolite and thus
prevent the accumulation of quinolinate from ACMS.

4-trimethylaminobutyraldehyde Dehydrogenase (ALDH9A1): This protein
belongs to the aldehyde dehydrogenase family of proteins. It has a high activity
for oxidation of gamma-aminobutyraldehyde and other amino aldehydes. The
enzyme catalyzes the dehydrogenation of gamma-aminobutyraldehyde to
gamma-aminobutyric acid (GABA). This isozyme is a tetramer of identical 54-kD
subunits.

Enoyl-CoA Hydratase And 3-Hydroxyacyl CoA Dehydrogenase (EHHADH):
his protein is involved in the pathway fatty acid beta-oxidation, which is part of
Lipid metabolism.

Amine Oxidase, Copper Containing 1 (AOC1): amine oxidase, copper
containing 1.This gene encodes a metal-binding membrane glycoprotein that
oxidatively deaminates putrescine, histamine, and related compounds. The
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encoded protein is inhibited by amiloride, a diuretic that acts by closing epithelial
sodium ion channels. Alternatively spliced transcript variants encoding multiple
isoforms have been observed for this gene.

Acyl-CoA Dehydrogenase Medium Chain (ACADM): This enzyme is essential
for converting these fatty acids to energy, especially during periods without food
(fasting). The ACADM enzyme functions in mitochondria, the energy-producing
centers within cells. It is found in the mitochondria of several types of tissues,
particularly the liver.

Aldehyde Dehydrogenase 18 Family Member A1 (ALDH18A1): Delta-1pyrroline-5-carboxylate synthetase (P5CS) is an enzyme that in humans is
encoded by the ALDH18A1 gene. This gene is a member of the aldehyde
dehydrogenase family and encodes a bifunctional ATP- and NADPHdependent mitochondrial enzyme with both gamma-glutamyl kinase and gamma
glutamyl phosphatereductase activities. The encoded protein catalyzes the
reduction of glutamate to delta1-pyrroline-5-carboxylate, a critical step in the de
novo biosynthesis of proline, ornithine and arginine. Mutations in this gene lead
to hyperammonemia, hypoornithinemia, hypocitrullinemia, hypoargininemia and
hypoprolinemia and may be associated with neurodegeneration, cataracts, and
connective tissue diseases. Alternatively spliced transcript variants, encoding
different isoforms, have been described for this gene.
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Aldehyde Dehydrogenase 4 Family Member A1 (ALDH4A1): This protein
belongs to the aldehyde dehydrogenase family of proteins. This enzyme is a
mitochondrial matrix NAD-dependent dehydrogenase which catalyzes the
second step of the proline degradation pathway, converting pyrroline-5carboxylate to glutamate. Deficiency of this enzyme is associated with type II
hyperprolinemia, an autosomal recessive disorder characterized by accumulation
of delta-1-pyrroline-5-carboxylate (P5C) and proline. Alternatively spliced
transcript variants encoding different isoforms have been identified for this gene.

Methylthioribulose 1-phosphate Dehydratase (APIP): Involved in
the methionine salvage pathway. APIP deficiency is associated with cell
death and cancer.

Arginase 2 (ARG2): Arginase catalyzes the hydrolysis of arginine to ornithine
and urea. At least two isoforms of mammalian arginase exists (types I and II)
which differ in their tissue distribution, subcellular localization, immunologic
crossreactivity and physiologic function. The type II isoform encoded by this
gene, is located in the mitochondria and expressed in extra-hepatic tissues,
especially kidney. The physiologic role of this isoform is poorly understood; it is
thought to play a role in nitric oxide and polyamine metabolism. Transcript
variants of the type II gene resulting from the use of alternative polyadenylation
sites have been described
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Argininosuccinate Lyase (ASL): An enzyme that catalyzes the reversible
breakdown of argininosuccinate (ASA) producing the amino acid arginine and
dicarboxylic acid fumarate. Located in liver cytosol, ASL is the fourth enzyme of
the urea cycle and involved in the biosynthesis of arginine in all species and the
production of urea in ureotelicspecies. Mutations in ASL, resulting low activity of
the enzyme, increase levels of urea in the body and result in various side effects.

Argininosuccinate synthetase (ASS1): An enzyme that in humans is encoded
by the ASS1 gene. The protein encoded by this gene catalyzes the penultimate
step of the arginine biosynthetic pathway. There are approximately 10 to 14
copies of this gene including the pseudogenes scattered across the human
genome, among which the one located on chromosome 9 appears to be the only
functional gene for argininosuccinate synthetase. Two transcript variants
encoding the same protein have been found for this gene.

3-methylglutaconyl-CoA hydratase (AUH): An enzyme encoded by
the AUH gene on chromosome 19. It is a member of the enoyl-CoA
hydratase/isomerase superfamily, but it is the only member of that family that is
able to bind to RNA. Not only does it bind to RNA, AUH has also been observed
to be involved in the metabolic enzymatic activity, making it a dual role protein.
Mutations of this gene have been found to cause a disease called 3Methylglutaconic Acuduria Type 1.
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Branched Chain Amino Acid Transaminase 2 (BCAT2): This gene encodes a
branched chain aminotransferase found in mitochondria. The encoded protein
forms a dimer that catalyzes the first step in the production of the branched chain
amino acids leucine, isoleucine, and valine. Multiple transcript variants encoding
different isoforms have been found for this gene.

Branched Chain Keto Acid Dehydrogenase E1, Alpha Polypeptide
(BCKDHA): 2-oxoisovalerate dehydrogenase subunit alpha, mitochondrial is
an enzyme that in humans is encoded by the BCKDHA gene. The second major
step in the catabolism of the branched-chain amino acids, isoleucine, leucine,
and valine, is catalyzed by the branched-chain alpha-keto acid dehydrogenase
complex (BCKD; EC 1.2.4.4), an inner-mitochondrial enzyme complex that
consists of 3 catalytic components:

Betaine-homocysteine S-methyltransferase (BHMT): This gene encodes a
cytosolic enzyme that catalyzes the conversion of betaine and homocysteine to
dimethylglycine and methionine, respectively. Defects in this gene could lead to
hyperhomocysteinemia, but such a defect has not yet been observed.

Carbamoyl-phosphate synthetase 2, Aspartate transcarbamylase, and
Dihydroorotase (CAD): Trifunctional multi-domain enzyme involved in the first
three steps of pyrimidine biosynthesis. De-novo synthesis starts
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with cytosoliccarbamoylphosphate synthetase II which uses glutamine, carbon
dioxide and ATP. This enzyme is inhibited by uridine triphosphate (feedback
inhibition).

Cystathionine-β-synthase (CBS): An enzyme (EC4.2.1.22) that in humans is
encoded by the CBS gene. It catalyzes the first step of the transsulfuration
pathway, from homocysteine to cystathionine: L-serine + L-homocysteine Lcystathionine + H2O. CBS uses the cofactor pyridoxal-phosphate (PLP) and can
be allosterically regulated by effectors such as the ubiquitous cofactor Sadenosyl-L-methionine (adoMet). This enzyme belongs to the family of lyases, to
be specific, the hydro-lyases, which cleave carbon-oxygen bonds. CBS is a
multidomain enzyme composed of an N-terminal enzymatic domain and two CBS
domains. The CBS gene is the most common locus for mutations associated
with homocystinuria.

Carbamoyl-phosphate Synthase 1 (CPS1): The mitochondrial enzyme
encoded by this gene catalyzes synthesis of carbamoyl phosphate from
ammonia and bicarbonate. This reaction is the first committed step of the urea
cycle, which is important in the removal of excess urea from cells. The encoded
protein may also represent a core mitochondrial nucleoid protein. Three
transcript variants encoding different isoforms have been found for this gene. The
shortest isoform may not be localized to the mitochondrion. Mutations in this
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gene have been associated with carbamoyl phosphate synthetase deficiency,
susceptibility to persistent pulmonary hypertension, and susceptibility to
venoocclusive disease after bone marrow transplantation

Cystathionine gamma-lyase (CTH): An enzyme which breaks
down cystathionine into cysteine, α-ketobutyrate, and ammonia. Pyridoxal
phosphate is a prosthetic group of this enzyme. Cystathionine gamma-lyase
also catalyses the following elimination reactions: L-homoserine to form H2O,
NH3 and 2-oxobutanoate; L-cystine, producing thiocysteine, pyruvate and NH3; Lcysteine producing pyruvate, NH3 and H2S. In some bacteria and mammals,
including humans, this enzyme takes part in generating hydrogen sulfide.
Hydrogen sulfide is one of a few gases that was recently discovered to have a
role in cell signaling in the body.

β2 microglobulin (B2M): A component of MHC class I molecules, which are
present on all nucleated cells (excludes red blood cells). In humans, the
β2 microglobulin protein is encoded by the B2M gene.
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